Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.

Revenue projections:

Revenue projections for REGN
Revenue projections for REGN

Regeneron Pharmaceuticals, Inc.'s revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 4.657000
forwardPE 12.910569
debtToEquity 8.612000
earningsGrowth -0.072000
revenueGrowth 0.190000
grossMargins 0.446000
operatingMargins 0.234790
trailingEps 40.960000
forwardEps 54.329130

Regeneron Pharmaceuticals, Inc.'s current ratio of 4.657 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that Regeneron Pharmaceuticals, Inc. is financially well-prepared to meet its liabilities without difficulty.
REGN's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
REGN's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.
REGN's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights REGN's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for REGN
Price projections for REGN

The price of Regeneron Pharmaceuticals, Inc. has remained consistently close to the lower limit of projections. This ongoing pattern raises concerns about the stock's performance and may reflect market hesitance regarding the company's growth prospects.

Insider Transactions:

Insider Transactions for REGN
Insider Transactions for REGN


8 Regeneron Pharmaceuticals, Inc. shares were sold in recent transactions, with market price at 748.8037567138672.No sell transactions were carried out during the period under review.The trend of more buys compared to sells around REGN's current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.

Recommendation changes over time:

Recommendations trend for REGN
Recommendations trend for REGN


REGN has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as REGN is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.